# Data Sheet (Cat.No.T2516)



# Amuvatinib

# **Chemical Properties**


CAS No.: 850879-09-3

Formula: C23H21N5O3S

Molecular Weight: 447.51

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



# **Biological Description**

| Description   | Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.   |  |  |  |
|---------------|---|--|--|--|
| Targets(IC50) | Apoptosis,FLT,c-RET,c-Kit,c-Met/HGFR,DNA/RNA Synthesis,PDGFR  |  |  |  |
| In vitro      | Tumor growth was inhibited by intraperitoneal injection of 10 mg/kg-75 mg/kg or by oral administration of 50 mg/kg-200 mg/kg MP-470 in a mouse transplantation tumor model harboring HT-29, A549, and SB-CL2 cells. The combination of 20 mg/kg MP-470 and erlotinib markedly inhibited the tumor growth in mice harboring LNCaP transplantation tumors. tumor growth in mice bearing LNCaP graft tumors.   |  |  |  |
| In vivo       | 1 μM MP-470 inhibited tyrosine phosphorylation of AXL in MDA-MB-231 cells.10 μM MP-470 caused cell cycle arrest in the G1 phase and decreased Akt and ERK1/2 phosphorylation in LNCaP cells.10 μM MP-470 inhibited c-Met phosphorylation in SF767 cells and sensitized the cells to radiation.10 μM MP-470 combined with radiation inhibited GSK-3β activity, induced apoptosis, and disrupted dsDNA b break repair, possibly by inhibiting Rad51. 470 inhibited GSK-3β activity and induced apoptosis in combination with radiation, and disrupted dsDNA b-break repair, possibly by inhibiting Rad51. MP-470 hydrochloride effectively inhibited the proliferation of OVCAR-3, A549, NCI-H647, DMS-153, and DMS-114 cells, with an IC50 of 0.9 μM to 7.86 μM. 7.86 μM. MP-470 was toxic to MiaPaCa-2, PANC-1 and GIST882 cells with IC50s ranging from 1.6 μM to 3.0 μM. MP-470 was toxic to LNCaP and PC-3 but not to DU145 cells with IC50s of 4 μM and 8 μM, respectively, and induced apoptosis at 10 μM. |  |  |  |
| Kinase Assay  | Kinase inhibition assay of c-Kit and PDGFR $\alpha$ : For the testing of inhibitory activity against c-Kit and PDGFR $\alpha$ , enzymes are incubated with varying concentrations of MP-470 and radiolabeled $\gamma$ -32P-ATP. After 30 min, the reaction mixtures are electrophoresed on an acrylamide gel and autophosphorylation, quantitated by the amount of radioactivity incorporated into the enzyme, is assayed.  |  |  |  |
| Cell Research | Cells are plated at a density of $2 \times 103$ to $1 \times 104$ cells per well in $100  \mu L$ medium on day 0 in 96-well Falcon microtitier plates. On day 1, ten $\mu L$ of serial dilutions of MP-470 are added to the plates in quadruplicates. After incubation for 4 days, the cells are fixed with 10% Trichloroacetic acid solution. Subsequently, they are labeled with 0.04% Sulforhodamine B (SRB) in 1% acetic acid. After multiple washes to remove the excess dye, 100 $\mu L$ of 50 mM Tris solution is added to each well in order to dissolve the dye. The absorbance of each well is read on a plate reader at 570 nm. Date are expressed as the  |  |  |  |

Page 1 of 2 www.targetmol.com

percentage of survival of control calculated from the absorbance corrected for background absorbance. The surviving percent of cells is determined by dividing the mean absorbance values of the monoclonal antibody by mean absorbance values of the control and multiplying by 100.(Only for Reference)

## **Solubility Information**

| Solubility | DMSO: 50 mg/mL (111.73 mM),Sonication is recommended.           |  |
|------------|---|--|
|            | Ethanol: < 1 mg/mL (insoluble or slightly soluble),             |  |
|            | (< 1 mg/ml refers to the product slightly soluble or insoluble) |  |

### **Preparing Stock Solutions**

|       | 1mg       | 5mg        | 10mg       |
|-------|-----------|------------|------------|
| 1 mM  | 2.2346 mL | 11.1729 mL | 22.3459 mL |
| 5 mM  | 0.4469 mL | 2.2346 mL  | 4.4692 mL  |
| 10 mM | 0.2235 mL | 1.1173 mL  | 2.2346 mL  |
| 50 mM | 0.0447 mL | 0.2235 mL  | 0.4469 mL  |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

#### Reference

Han H W, Hahn S, Jeong H Y, et al. LINCS L1000 dataset-based repositioning of CGP-60474 as a highly potent antiendotoxemic agent. Scientific Reports. 2018 Oct 8;8(1):14969

Hurley LH, et al. World Patent, WO/2005/037825.

Mahadevan D, et al. Oncogene, 2007, 26(27), 3909-3919.

Qi W, et al. BMC Cancer, 2009, 9, 142.

Welsh JW, et al. Radiat Oncol, 2009, 4, 69.

Han H W, Hahn S, Jeong H Y, et al. LINCS L1000 dataset-based repositioning of CGP-60474 as a highly potent antiendotoxemic agent[J]. Scientific reports. 2018 Oct 8;8(1):14969.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:36 Washington Street, Wellesley Hills, MA 02481

Page 2 of 2 www.targetmol.com